

Supplement 2. Disclosure of Interest

Forms of the ASH ISTH NHF WFH

Guideline Panel on the Diagnosis of Von

Willebrand Disease

Barbara Ameer

Nathan T. Connell

Jorge Di Paola

Jeroen Eikenboom

Nicolas Giraud

Sandra Haberichter

Vicki Jacobs-Pratt

Paula D. James

Barbara Konkle

Claire McLintock

Simon McRae

Robert Montgomery

Reem A. Mustafa

James S. O'Donnell

Nikole Scappe

Robert Sidonio Jr.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
PrO Unlimited	Contracted consultant in diabetes (for Sanofi)	Paid	March 2016	Not a COI , this relationship ended prior to appointment.
Snow Companies	Service on coagulation patient advocacy board (for CSL Behring)	Unpaid	March 2017	Not a COI , this relationship ended prior to appointment.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

The reaction from peers is unlikely to adversely impact me.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 3/12/2018; Kunkle, 4/2/2018; Lottenberg, 5/10/2018	No	No	Dr. Ameer does not have any direct or indirect financial COIs with companies that could be affected by the guidelines. She reports one recent unpaid in a patient advocacy board for CSL Behring, this activity ended prior appointment to the guideline panel.
Castano, 07/14/2020	No	No	On July 1, 2020 Dr. Ameer confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Ameer is serving as a patient representative on the guideline panel.
--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novimmune	An observational, multicenter study to evaluate interferon gamma (IFN̄) and other inflammatory mediators in Adult Patients with hemophagocytic lymphohistiocytosis (A-HLH)	Site subinvestigator to enroll patients	Current	Not a COI. Novimmune does not market any products for the diagnosis or treatment of VWD.
Genentech; Hoffmann-La Roche	A randomized, multicenter, open-label, phase iii clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in	Site subinvestigator to enroll patients	Current	Not a COI. Dr. Connell does not have a leadership role in this study. Genentech and Hoffmann-LaRoche do not market any products for the diagnosis or

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	hemophilia A patients without inhibitors			treatment of VWD. Dr. Connell does not have a leadership role in this study.
Daiichi	A Phase 3B, Prospective, Randomized, Open-Label, Blind Evaluator (Probe) Study Evaluating the Efficacy and Safety of (LMW) Heparin / Edoxaban Versus Dalteparin in Venous Thromboembolism Associated with Cancer	Site subinvestigator to enroll patients	Current	Not a COI. Daiichi does not market any products for the diagnosis or treatment of VWD.
Bristol-Myers Squibb	Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS0986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)	Site subinvestigator to enroll patients	12/8/16 (no patients enrolled at site prior to closure)	Not a COI. BMS does not market any products for the diagnosis or treatment of VWD.
Pharmacosmos AS	A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia who are intolerant or unresponsive to oral iron therapy or in whom the haemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.	Site subinvestigator to enroll patients	Current	Not a COI. Pharmacosmos AS does not market any products for the diagnosis or treatment of VWD.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

I am a local clinician in the field of benign hematology which includes topics of thrombosis and hemostasis. I see patients clinically in these fields and teach about the diagnosis and management of hematologic disorders to medical students, medical residents, hematology/oncology fellows based on currently published evidence-based guidelines.

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have strong institutional support from the Brigham and Women's Hospital Division of Hematology to participate in these guidelines and believe they would support evidence-based recommendations that would result from the process.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
ISTH	ISTH has published various papers to try and standardize the terminology and diagnosis of VWD. They are participating in these guidelines.	Member

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

Hematology with a focus on thrombosis and hemostasis

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain:

I prescribe various treatments for von Willebrand disease such as plasma-derived factor, recombinant factor, antifibrinolytics, and DDAVP as appropriate and supported by published evidence.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
 Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Global Blood Therapeutics, Inc.	Site sub-investigator to enroll patients for a Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease (ongoing)	10/29/2017	Not a COI. Global Blood Therapeutics does not market any products for the diagnosis or treatment of VWD.
Genentech; Hoffmann-La Roche	Update, this activity ended on March 31, 2017 See part B.	1/09/2020	Not a COI.
Daiichi	Update, this activity ended on 5/2/2018 See part B.	1/09/2020	Not a COI.
Bristol-Myers Squibb	Update, this activity ended on 12/8/2016 See part B.	1/09/2020	Not a COI.
Pharmacosmos AS	This activity ended and the institution closed on 1/25/2018. See part B.	1/09/2020	Not a COI.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 7/27/17; Kunkle, 4/2/18; Djulgovic, 5/07/2018	No	No	Dr. Connell has no current direct or indirect financial conflicts of interest with companies that market products that could be affected by guidelines on the diagnosis or treatment of von Willebrand disease.
Castano, 1/9/2020	No	No	Dr. Connell updated his disclosures to report end dates to several research activities he has been involved in. Dr. Connell has no current direct or indirect financial conflict of interest.
Castano, 7/14/2020	No	No	On 7/01/2020 Dr. Connell confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Connell is a hematologist specializing in thrombosis and hemostasis. In his clinical practice, he treats patients with von Willebrand disease. For his institution, he teaches medical students, residents, and fellows about the diagnosis and management of hematologic disorders. As a site sub investigator, he enrolls patients into research studies that are funded by pharmaceutical companies; however, none of the companies markets products used for the diagnosis or treatment of von Willebrand disease.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Consultant	10-2017	Not a COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to appointment to the guideline panel and Dr. Di Paola has agreed to avoid direct financial conflicts with affected companies for the duration of guideline development.
Shire	Consultant	3-2017	Not a COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to appointment to the guideline panel and Dr. Di Paola has agreed to avoid direct financial conflicts with affected companies for the duration of guideline development.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Review article in Blood, chapter in Self-Assessment Program of the American Society of Hematology

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NIH-NHLBI (R01)	A systems biology approach to bleeding	Principal Investigator	07/2019

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I always feel supported by my Institution

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Pediatric Hematology Oncology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I participate actively in the diagnosis and treatment of patients with von Willebrand Disease

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	NHLBI Award R61HL141794 NHLBI A systems biology approach to identifying the mechanisms of sex hormone induced thromboembolism in pre-menopausal women” Duration 04/01/2018 – 03/31/2023 Role: Principal Investigator (Multiple PI mechanism)	7/9/2018	Not a COI
N/A	Mountain States Hemophilia Network Award H30MC24049 Maternal and Child Health Bureau/HRSA/DHHS Duration: 07/01/2017 – 06/30/2022 Role: Co-Investigator “ Genomics of Bleeding Disorders”	7/9/2018	Not a COI
CSL Behring	Honoraria and Travel	9/24/2019	Direct COI. CSL Behring is a pharmaceutical company that markets human plasma-derived von Willebrand factor and FVIII (HP-VWF/FVIII) concentrate and nasal desmopressin for treatment VWD. Desmopressin is also used for the diagnosis

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			of VWD in what is known as the Desmopressin trial.
N/A	NIH/NHLBI R01HL120728 No cost extension, A system biology approach to predicting bleeding in hemophilia Principal Investigator (Multiple PI mechanism) 09/30/2014-07/01/2020	07/09/2020	Not a COI
N/A	NIH/NHLBI PAR18-024 Zimmerman Program on the Biology of VWD, Principal Investigator Core B Genomics and Bioinformatics Core; P01 Principal Investigator: Robert Montgomery, MD - 03/15/2019 – 02/28/2024	07/09/2020	Not a COI
N/A	NIH/NHLBI R01 HL139825-01 Genomics of Megakaryocytes and Platelet Biology, Principal Investigator, 02/01/2020 – 01/31/2025	07/09/2020	Not a COI

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 11/29/17; Castano, 03/26/2018; Kunkle, 4/2/18; Djulgovic, 5/07/2018	No	No	Dr. Di Paola does not have current direct or indirect financial COIs with companies that could be affected by the guidelines. He reports two recent paid consulting activities with Shire and CSL Behring, but he has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.
Castano, 6/01/2018	No	No	Dr. Di Paola disclosed two additional awards from WHF and MCHB. Please see part D for details.
Castano, 11/21/2019	Yes	No	Dr. Di Paola disclosed one talk sponsored by CSL Behring for which he received travel support and honoraria in February of 2018. This activity was judged to be a direct financial conflict and was managed through recusal. See part D for details.
Castano, 07/14/2020	Yes	No	On July 9, 2020 Dr. Di Paola disclosed 3 NIH grants that do not constitute conflicts of interests. Please see part D for details. On July 14, 2020 Dr. Di Paola confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
CSL Behring	Honoraria and travel for a talk in February 2018.	9/4/2019	See above.

Other Notes

Dr. Di Paola is a pediatric hematologist/oncologist. In his clinical practice, he diagnoses and treats patients with VWD. He is the principal investigator for a research project funded by the National Heart, Lung and Blood Institute about a systems biology approach to bleeding. He co-authored a chapter title [Bleeding disorders](#) in ASH's *Self-Assessment Program* and he authored a review article in *Blood*, titled [Paris-Trousseau: evidence keeps pointing to FLI1](#).



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Roche	<p>Educational lecture at the Dutch “ASH Review”. Lecture was NOT related to the subject of the guideline.</p> <p>Remark: Honorarium was not transferred to me personally, but to my institute.</p>	Dec 16, 2015	<p>Not a COI. Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche also markets a product for the prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors. This activity concluded prior to initiation of the guidelines, and Dr. Eikenboom has agreed to avoid direct financial conflicts for the duration of the guideline development process.</p>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	Description of Research	My Role	End Date	For ASH Internal Use
CSL Behring	<p>An investigator initiated study: Evaluation of Blood Outgrowth Endothelial Cells as a strategy for determining pathogenic mechanisms and potential therapies for bleeding disorders.</p> <p>This study is a collaboration with Queen's University, Kingston, Ontario, Canada</p>	National principle investigator of the study	Ongoing Will end December 2018	Indirect COI. CSL Behring markets human plasma-derived von Willebrand factor FVIII concentrate, and nasal desmopressin for treatment VWD. Desmopressin is also used for the diagnosis of VWD in what is known as the Desmopressin trial.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have coauthored review papers and guidelines on this subject. The views presented in those papers are reflecting the data in the literature and are not reflecting a personal opinion:

- Leebeek FWG, Eikenboom JCJ. Von Willebrand's disease. *New England Journal of Medicine* 2016; 375:2067-2080
- De Jong A, Eikenboom J. Developments in the diagnostic procedures of von Willebrand disease. *Journal of Thrombosis and Hemostasis* 2016;14:449-460

- Principles of care for the diagnosis and treatment of von Willebrand disease. Castaman G, Goodeve A, Eikenboom J. Haematologica 2013;98:667-674.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Landsteiner Foundation for Blood Transfusion Research (nonprofit foundation)	Development of RNA-targeted therapies for bleeding disorders, especially von Willebrand disease	Overall Principle investigator	Ongoing Will end by November 2018

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I don't know. I presume that this would not affect my position in any way.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

Internal medicine, subspecialty hematology and vascular medicine

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain:

I see patients with von Willebrand disease and I'm involved in diagnosing patients with Von Willebrand disease. In that capacity I will order laboratory tests that will be addressed in these guidelines.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
 Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
CSL Behring	2017 Funding for managing a Von Willebrand factor research consortium consisting of the Leiden University Medical Center (Dr. Eikenboom), Sanquin Research Amsterdam (Dr. Voorberg) and Erasmus University Medical Center (Dr. Leebeek). This same funding was granted in 2018.	6/8/2018	Indirect COI. As noted above, CSL Behring markets products that can be affected by the guidelines.
Roche	Educational lecture at the ASH meeting of 2018. Lecture NOT related to the subject of the guideline. Remark: Honorarium not transferred to me personally, but to my institute.	6/08/2018	Indirect COI. As noted above, Roche markets products that can be affected by the guidelines. This is indirect because Dr. Eikenboom is not receiving direct payments from Roche, the fee is transfer to his institution.
Celgene	Educational lectures at the Dutch "ASH Review 2018". Lectures were NOT related to the subject of the guideline. Remark: Honorarium for this was not transferred to me personally, but to my institute.	9/04/2019	Not a COI. Celgene does not market any products for the treatment or diagnosis of VWD.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Roche	Educational lectures at the Dutch “ASH Review 2018”. Lectures were NOT related to the subject of the guideline. Remark: Honorarium for this was not transferred to me personally, but to my institute.	9/04/2019	Indirect COI. As noted above, Roche markets products that can be affected by the guidelines. This is indirect because Dr. Eikenboom is not receiving direct payments from Roche, the fee is transfer to his institution.
Roche	Covered partial travel to attend ASH Annual Meeting in 2018.	9/04/2019	Direct COI. Roche is a pharmaceutical and diagnostic company that markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US.
CSL Behring	Funding for the research activity outlined in part B ended in December 2018, but new funding was received to continue the activity as described.	9/04/2019	Indirect COI. See part B.
N/A	The funding from Landsteiner Foundation for Blood Transfusion Research indicated in part B has ended.	9/04/2019	Not a COI.
N/A	Dr. Eikenboom received new funding from the Landsteiner Foundation for Blood Transfusion Research for the project “Disease in a dish: Modelling Von Willebrand disease with patient-specific	9/04/2019	Not a COI. This is non-industry funded research.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	induced pluripotent stem cells". His role is 'overall PI. Start date April 1, 2019, end date March 31, 2022.		
N/A	Dr. Eikenboom obtained funding from the Netherlands Thrombosis Foundation for the project "Lowering von Willebrand factor as a therapeutic approach to reduce the risk of arterial thrombosis". His role is 'overall PI. Start date March 1, 2019, end date February 28, 2023	9/04/2019	Not a COI. This is non-industry funded research.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 11/29/17; Castano, 03/21/18; Kunkle, 4/2/18, Lottenberg, 5/10/2018	No	Yes	Dr. Eikenboom has one indirect financial conflict. He is the national PI for a research study funded by CSL Behring on the role of blood outgrowth endothelial cells in bleeding disorders. This activity will end in December 2018.
Castano, 6/08/2018	See above	Yes	Dr. Eikenboom reports two potential COI, see part D, with Roche and CSL Behring, companies that may be affected by the guidelines.
Castano, 11/21/2019	Yes	Yes	Dr. Eikenboom disclosed one direct financial relationship (travel) and one indirect (talk for which the fee was paid to his institution) with Roche. He also disclosed a new research activity with CSL Behring, which is an indirect conflict of interest. The direct conflict with Roche was managed through recusal.
Castano, 7/14/2020	Yes	Yes	On 7/1/2020 Dr. Eikenboom confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Roche	Covered partial travel to attend ASH Annual Meeting in 2018.	9/04/2019	Direct COI

Other Notes

Dr. Eikenboom specializes in internal medicine and hematology. In his clinical practice, he diagnoses and treats patients with VWD. He has co-authored several articles, see above, about the diagnosis and treatment of VWD. In addition to the CSL Behring-funded study described above, Dr. Eikenboom is the PI for research on the development of RNA-targeted therapies for bleeding disorders, especially VWD, funded by the nonprofit Landsteiner Foundation for Blood Transfusion Research.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Association Française des Hémophilies (AFH) French Hemophilia Society	Executive board member of AFH /President of the von Willebrand peer group/ Trained as a patient expert to conduct and elaborate with health care professionals empowerment sessions	Unpaid	ongoing	
Association Française des Hémophilies, et Malades de Willebrand ou autres troubles de l’hémostase - comité Provence-Alpes-Côte d’Azur Corse (AFHW PACA-Corse) Local chapter of AFH	Board member/ Representative of the chapter at the national von Willebrand peer group	Unpaid	ongoing	
World Federation of Hemophilia (WFH)	Member of the WFH von Willebrand disease patient organizations group	Unpaid	ongoing	
French von Willebrand reference center (CRMW)	Executive board Member	Unpaid	ongoing	

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? No impact for me

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Shire Human Genetic Therapies Inc.	Member of an oversight group (Expert Reference Group) for an observational study conducted by HCD Economics investigating the economic burden of illness for von Willebrand's disease (vWD) in adult and paediatric patients in Europe. HCD Economics is a public-private research institution associated with the University of Chester.	4/19/2018	Indirect COI. Shire markets products for the treatment of VWD and may be affected by the guidelines. Mr. Giraud will not receive any payments or other transfers of value for this activity.
N/A	Mr. Giraud will participate in a one-hour patient meeting called by the European Medical Agency (EMA). During this meeting, the patient group will discuss whether to maintain or not the nomination of an orphan drug and molecule owned by Shire.	7/13/2018	Not a COI. EMA is the regulatory body of the European Union and it is not funded by industry.
N/A	President of the French Haemophilia Association	08/06/2019	Indirect COI. In his role as President of the French Haemophilia Association, Mr. Giraud is in charge of financial operations of the society which include

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			activities with pharmaceutical companies that may be affected by the guidelines. He is not receiving payments or transfers of value for this role.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 3/27/2018; Kunkle, 4/2/2018	No	No	Mr. Giraud does not have any direct or indirect financial COIs with companies that could be affected by these guidelines.
Castano, 5/01/2018; Kunkle 5/4/2018; Djulgovic 7/07/2018	See above	Yes	New disclosure: See Part D. Mr. Giraud is participating on an oversight group for an observational study about pediatric VWD sponsored by Shire, a company that may be affected by the guidelines. He will not receive any payments or any direct transfers of value for this activity.
Castano, 7/13/2018	See above	No	New disclosure: see Part D. Mr. Giraud is participating in a patient group called by EMA to evaluate the orphan status of a drug/molecule own by Shire. He will not receive any payments or any direct transfers of value for this activity.
Castano, 8/6/2019	No	Yes	New disclosure: See Par D. Mr. Giraud disclosed that he was elected President of the French Haemophilia Association. Although the position is unpaid and he will not be receiving any direct transfers of value or payments, he will be in charge of signing for and authorizing all financial operations which may include activities with pharmaceutical companies.
Castano, 7/20/2020	No	Yes	On July 2, 2020 Mr. Giraud confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Mr. Giraud is serving as a patient representative on the guideline panel. He is a member of the executive board of the Association Française des Hémophilies, and he is the president of their VWD peer group. He is also a member of a VWD patient group organized by the World Federation of Hemophilia. He is trained to conduct empowerment sessions with health care professionals. All these roles are unpaid.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I feel my institution would support my work on this panel regardless of reaction from others outside the institution.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	Update 12/10/2019 Employment at Versiti BloodCenter of Wisconsin		Indirect COI. Versiti BloodCenter of Wisconsin is not a for-profit company, involved in the diagnosis of VWD and therefore could be affected by the recommendations.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 11/29/17; Castano, 03/20/18; Kunkle, 4/2/18; Lottenberg 5/10/2018	No	No	Dr. Haberichter does not have any financial direct or indirect COI.
Castano, 12/10/2019	No	Yes	Dr. Haberichter is employed by Versiti BloodCenter of Wisconsin, has proprietary tests for VWD and could be affected by these guidelines.
Castano, 7/14/2020	No	Yes	On July 7, 2020 Dr. Haberichter confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Haberichter is the Lab Director, Hemostasis, at the BloodCenter of Wisconsin and an Associate Professor of Pediatrics at the Medical College of Wisconsin. The laboratory could be affected by recommendations against VWD testing but not by recommendations about which tests to use. The BloodCenter of Wisconsin has proprietary tests for VWD and could be affected by these guidelines, depending on the tests addressed by the guideline recommendations.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Baxalta US Inc. (Shire)	Patient/Caregiver Advisory Board	6/16/2017 was the last contact.	<p>Not a COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment This activity concluded prior to initiation of the guidelines, and Ms. Jacobs-Pratt has agreed to avoid financial conflicts with affected companies for the duration of the</p>

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			guideline development process.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Hemophilia Alliance of Maine	Executive Director	Paid	10/21/16	Not a COI. This activity ended prior to appointment to the guidelines panel, and the alliance is a non-profit organization.
National Hemophilia Foundation	Women’s Task Force	Unpaid	No contact for months	Not a COI. NHF is a non-profit organization.
Hemophilia Federation of America	Board Member Scholarship Review Committee	Unpaid Unpaid	10/21/16 current	Not a COI. HFA is a non-profit organization, and the positions are unpaid.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain: I am prescribed and use one of the products from a for-profit company.

ASH internal note: the pharmaceutical company that manufactures the medication, does not reimburse or subsidize the medication in any way.

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Since I have Von Willebrand's Disease, I have paid close attention to emerging therapies and treatment protocols to actively advocate and manage my VWD to obtain the optimum quality of life for myself as I age.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have presented at various consumer based meetings over the last 15 years, though not in the last 18 months, and have most likely provided an opinion a time or two.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Career Advancement is a non-issue for me as I am retired but I think I would receive great support for my work on this project from all entities.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 03/27/2018; Kunkle, 4/2/18; Lottenberg, 5/19/2018	No	No	Ms. Jacobs-Pratt does not have any direct or indirect financial COIs with companies that could be affected by the guidelines. In 2017, prior to her appointment to the guideline panel, she was a paid participant on an advisory board for Baxalta (Shire), but she has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.
Castano, 7/14/2020	No	No	On 7/14/2020 Ms. Ms. Jacobs-Pratt confirmed all the information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Ms. Jacobs-Pratt is serving as a patient representative on the guideline panel. She is the former Executive Director of the Hemophilia Alliance of Maine. She is also a member of a women's task force for the National Hemophilia Foundation, and she is a board member for the Hemophilia Federation of America. All these roles are unpaid. She has presented at various consumer-based meetings about VWD.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Please note that the honoraria associated with these Advisory Boards goes into an institutional education account, and is detailed below in Part B, section 3.

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Baxalta/Shire	Travel support, meals	September 24, 2016	Not a COI. This relationship concluded prior to Dr. James's appointment, and she has agreed to avoid direct financial relationships with Baxalta/Shire going forward.
CSL Behring	Travel support, meals	September 19, 2015	Not a COI. This relationship concluded prior to Dr. James's appointment, and she has agreed to avoid direct financial relationships with CSL Behring going forward.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Baxter/ Baxalta/Shire	Investigator Initiated Grant for the project "Examination of the Critical Role of High Molecular Weight von Willebrand Factor in Angiodysplasia"	PI	ongoing	Indirect COI. Shire/Baxalta markets a recombinant von Willebrand factor and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease not responding to other treatments. These guidelines may indirectly affect the use of these products, by increasing or decreasing the number of patients for whom the products could be indicated. Dr. James has a leadership role in this research, but all funding goes to her institution rather than to her directly.
CSL Behring	Investigator Initiated Grant for the project "Community Self-BAT Knowledge Translation"	PI	ongoing	Indirect COI. CSL Behring markets a human plasma-derived von Willebrand factor concentrate and a nasal desmopressin for the treatment of VWD. These guidelines may indirectly affect the use of these products by increasing or decreasing the number of patients for whom the products could be indicated. Dr. James has a leadership role in this research, but all funding goes to her institution rather than to her directly.
CSL Behring	Investigator Initiated Grant for the project "Evaluation of Blood Outgrowth Endothelial Cells as a Strategy for Determining Pathogenetic Mechanisms and Potential Therapies for Bleeding Disorders"	Co-investigator	ongoing	Not a COI. Dr. James does not have a leadership role in this research.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bayer	Educational Support for Trainees – Unrestricted Educational Grant	Co-investigator	Ongoing	Not a COI. Dr. James does not have a leadership role in this research.
Bayer	Investigator Initiated Grant for the project “Validation of the ISTH-BAT in Hemophilia Carriers”	PI	June 30, 2016	Not a COI. This study concluded prior to Dr. James’s appointment.
Octapharma	Industry Sponsored Study “Surveillance and Efficacy of Wilate in Patients with von Willebrand Disease”	Site investigator	December 31, 2015	Not a COI. This study concluded prior to Dr. James’s appointment.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Canadian Hemophilia Society	Chair/Member of the Research Advisory Committee	Unpaid	ongoing	Not a COI. This is an unpaid role with a nonprofit organization that is not expected to be affected by guidelines on diagnosis of VWD.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

I have participated in Advisory Boards and given presentations for the companies listed below in the past 24 months, but do not directly keep any of the money. It is deposited into an institutional educational account and used to fund travel to meetings for my team. Baxalta/Shire, CSL Behring.

Indirect COI. Dr. James receives no direct payments or transfers of value for these ongoing activities. However, her institution and team benefits. As described above under Part B, Question 1, Baxalta/Shire and CSL Behring market products used to manage VWD. These diagnostic guidelines may indirectly affect the use of these products, e.g., by increasing or decreasing the number of patients for whom the products could be indicated.

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I regularly give invited presentations about VWD. To summarize my views: 1) Bleeding Assessment Tools are useful in diagnosing VWD, 2) genetic testing is useful for Types 2 and 3 VWD, but not Type 1 VWD, 3) emerging data shows that individuals with VWF levels < 0.30 IU/mL have more bleeding at diagnosis and bleed more over time. Below is a list of presentations made in the past 24 months.

“Controversies in the diagnosis of type 1 von Willebrand disease” International Society of Laboratory Hematology (ISLH) 2017 Honolulu, Hawaii, May 5, 2017.

“Perioperative Bleeding in a Child without a Bleeding History” Case session ASH Satellite Symposium, San Diego, California, December 2, 2016.

“Acquired von Willebrand syndrome” Canadian Hemophilia Physician Update 2016, Montreal, Canada, September 24, 2016

“Clinical Management of VWD and Women’s Disorders” Case Session ISTH Advanced Training Course in Thrombosis and Hemostasis, Oxford, UK, September 8, 2016

“Disorders of Hemostasis” 2016 Highlights of ASH North America, New York, New York, January 29, 2016

“Disorders of Hemostasis” 2016 Highlights of ASH North America, Toronto, Ontario, January 15, 2016

“Using Genetic Diagnostics in Hemophilia and von Willebrand Disease” ASH Education Program: Guiding Hematologic Care with Genetic Testing, Orlando, Florida, December 7, 2015

Review articles published in the past 24 months on VWD are listed below. The views I expressed in these publications are consistent with the summary above for presentations.

Bowman M, James P. Controversies in the diagnosis of Type 1 von Willebrand disease. Accepted by International Journal of Laboratory Hematology February 2017

Selvam S.N, James P. Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science. Accepted by Seminars in Thrombosis and Hemostasis. February 2017

Goodeve A, James P. von Willebrand Disease (January 2017) in: GeneReviews at GeneTests: Medical Genetics Information Resource. Available at <http://www.genetests.org>. PMID: 20301765

Swystun L.L, James P. Genetic Diagnosis in Hemophilia and von Willebrand disease. Blood Rev. 2017 Jan;31(1):47-56. doi: 10.1016/j.blre.2016.08.003. Review. PMID: 27596108

Reynen E, James P. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion. Semin Thromb Hemost. 2016 Oct;42(7):717-723. PMID: 2764861

Bowman M, James P. Bleeding scores for the diagnosis of von Willebrand disease. Semin Thromb Hemost. 2017 Feb 14. doi: 10.1055/s-0036-1597289. [Epub ahead of print] PMID: 28196380

Swystun LL, James P. Using genetic diagnostics in hemophilia and von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):152-9. doi: 10.1182/asheducation-2015.1.152. PMID:26637715

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
National Institutes of Health	Zimmerman Program Project Grant on the Clinical and Molecular Biology of von Willebrand Disease	Co-investigator	ongoing
Canadian Hemophilia Society	Research grant for the project “Angiodysplasia in von Willebrand disease: Studies Using Patient-derived BOEC (Blood Outgrowth Endothelial Cells)	PI	June 30, 2017

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don’t know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would receive complete support from my primary mentor and my institution.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I regularly diagnose and manage patients with VWD.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	HTRS, Scientific Symposium Co-Chair – April 2019 one time.	11/18/2018	Not a COI.
Octapharma	Co-investigator for study on VWF Concentrate to treat menorrhagia in women with VWD.	12/11/2018	Indirect COI. Octapharma markets a VWF replacement therapy for the treatment of patients with VWD. They also market a recombinant factor VIII product for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
CSL Behring	Update: the activity below ended on May 31 2018, and its no longer an indirect COI. PI: Investigator Initiated Grant for the project "Community Self-BAT Knowledge Translation" See part B	1/07/2020	Not a COI.
Bayer	Update: the activity below ended on December 31, 2019 Co-Investigator: Educational Support	1/07/2020	Not a COI.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	for Trainees – Unrestricted Educational Grant		
Bayer	Research Grant from Bayer starting April 2020 - March 2021. Project title: Let's Talk Period for Hemophilia Carriers	7/2/2020	Not a COI. Bayer is not an affected company.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 7/27/17; Kunkle 9/1/17; Panepinto, Flowers, Iorio, Lottenberg, Majhail, Pai 9/7/17	No	Yes	As a condition of her appointment, Dr. James has agreed to avoid all direct financial conflicts of interest during the guideline development process. She has indirect financial conflicts, including serving in a leadership role on research projects funded by companies that market products for the management of VWD, i.e., Baxalta/Shire and CSL Behring. Dr. James also reports ongoing participation in advisory boards for these same companies, for which she receives no direct payments or transfers of value; all payments are made to her institution. These diagnostic guidelines may indirectly affect the use of products marketed by these companies, e.g., by increasing or decreasing the number of patients for whom the products could be indicated. These indirect conflicts will be managed by disclosure and by including a vice-chair and a co-chair on the guideline panel who do not have conflicts. If Dr. James has an indirect financial conflict relevant to a guideline question or recommendation, the vice-chair or co-chair will assume the chair role.
Kunkle 4/2/18	No	Yes	"Other Notes" added below.
Castano, Kunkle 7/10/18	No	Yes	Dr. James reports that since appointment, she is no longer participating in industry advisory boards.
Castano, 11/19/2018	No	Yes	Dr. James reports that she is a Co-chair for an HTRS Scientific Symposium to be taking place in 2019. This is a one-time appointment to end once the symposium is over.

Castano, 12/12/2018	No	Yes	Dr. James reports participation on one research studies funded by Octapharma about the use of VWF to treat menorrhagia in women with VWD. Octapharma makes products for the treatment of VWD that can be affected by the guidelines.
Castano, 1/07/2020	No	Yes	Dr. James reports that a research activity sponsored by CSL Behring, that was led by her ended on May 31, 2019. Therefore, this activity is no longer an indirect financial conflict, see parts B and D for details.
Castano, 7/14/2020	No	Yes	On July 2, 2020 Dr. James disclosed a new research grant for Bayer for Hemophilia, which is not a conflict of interest, see part D. On July 2, 2020 Dr. James also confirmed all the information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. James is a hematologist. In her clinical practice, she regularly diagnoses and manages patients with VWD. In addition to the company-funded research described above, she is a co-investigator on a study of the clinical and molecular biology of VWD, funded by the National Institutes of Health. She regularly gives invited presentations about the diagnosis of VWD.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Biomarin	Member of independent DSMB for hemophilia gene therapy trial	ongoing	Not a COI. BioMarin markets products for rare genetic diseases that do not include bleeding disorders. They have one pipeline product in Phase 2 for treatment of hemophilia A.
CSL Behring	Member of independent data monitoring committee for a FIX product	Ongoing	Indirect COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Genentech/Roche	Consulting on development of new impact scale in hemophilia	Ongoing	Direct COI. Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche also markets a product for the prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors.
Green Cross	Dinner and honorarium for meeting at ASH 2016	12/2016	Not a COI. Green Cross markets plasma derivatives, including a concentrated antihemophilic factor VIII indicated for the treatment of hemophilia A. They do not have any marketed or pipeline products for the diagnosis or treatment of VWD. This activity concluded prior to appointment to the guideline panel.
Grifols	Honorarium for talk given about ADAMTS13 in Koate at ISTH SSC 2016	5/2016	Not a COI. Grifols markets an antihemophilic factor/von Willebrand factor complex indicated for the treatment of VWD in patients for whom desmopressin is either ineffective or contraindicated. This activity concluded prior to appointment to the guideline panel.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Advisory board on gene therapy, VOICE activity to increase awareness of VWD	Adv. Board 5/2016; VOICE 9/2017	Not a COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Both activities concluded prior to appointment to the guideline panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Abbott Laboratories	Equity ownership	ongoing	Not a COI. Abbott Laboratories markets automated hematology analyzers for use in clinical laboratories. The analysis performed by these devices is applicable to a variety of hematologic conditions but is not specific to VWD. The impact of these guidelines on the company is therefore expected to be trivial.
Bristol Meyers Squibb	Equity ownership	ongoing	Not a COI. BMS does not market any products for the diagnosis or treatment of bleeding disorders.
CVS	Equity ownership	ongoing	Not a COI. CVS does not market any products for the diagnosis or treatment of bleeding disorders.
Glaxo Smith Kline	Equity ownership	ongoing	Not a COI. GSK does not market any products for the diagnosis or treatment of bleeding disorders.
General Electric	Equity ownership	ongoing	Not a COI. General Electric does not market any products for the diagnosis or treatment of bleeding disorders.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Johnson and Johnson	Equity ownership	ongoing	Not a COI. Johnson and Johnson does not market any products for the diagnosis or treatment of bleeding disorders.
Merck	Equity ownership	ongoing	Direct COI. Merck markets an estrogen contraceptive product that could be used in the management of VWD symptoms in women. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Novartis	Equity ownership	ongoing	Not a COI. Novartis does not market any products for the diagnosis or treatment of bleeding disorders.
Roche	Equity ownership	ongoing	Direct COI. As noted above, Roche markets products for the diagnosis and treatment of VWD.
Siemens	Equity ownership	ongoing	Not a COI. Siemens markets automated hematology and hemostasis analyzers for use in clinical laboratories. The analysis performed by these devices is applicable to a variety of hematologic conditions but is not specific to VWD. The impact of these guidelines on the company is therefore expected to be trivial.

ASH staff note: By e-mail on March 14, 2018, Dr. Konkle explained that the market value of the above holdings is >\$10,000 each and >\$200,000 in aggregate.

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bioverativ	MyLifeOurFuture, a genetics project in hemophilia	P.I.	6/30/18	Indirect COI. Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
Bioverativ/ Sanofi	Clinical trial of a longer acting FVIII product	Site P.I.	ongoing	Indirect COI. As noted above, Bioverativ markets a product that can be used in the treatment of VWD.
Bioverativ	B-Natural, data collection on siblings with hemophilia B	Site P.I.	N/A	Not a COI. Dr. Konkle’s team was unable to recruit any subject so her participation in this study ended, see part D.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Octapharma	Central lab for post-marketing study for markers of thrombosis	Lab director	11/2016	Not a COI. Octapharma markets a VWF replacement therapy for the treatment of patients with VWD. They also market a recombinant factor VIII product for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This study ended prior to the start of the guidelines.
Sangamo	Gene therapy trial in hemophilia	Site P.I.	ongoing	Not a COI. Sangamo has two pipeline products currently under investigation for the treatment of patients with hemophilia A and factor IX deficiency. They do not currently market any products indicated for the diagnosis or treatment of VWD.
Shire/ Takeda	AAV immunity prevalence study	Site P.I.	8/2018	Indirect COI. As noted above, Shire markets products that can be used for the treatment of VWD.
Shire/ Takeda	Gene therapy trial in hemophilia	Site P.I.	N/A	Not a COI. Dr. Konkle’s team never finalized the contract for this study, therefore she is not participating in this study. See part D

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Foundation for Women and Girls with Blood Disorders	Board Member	Unpaid	ongoing	Not a COI. Foundation for Women and Girls with Blood Disorders is a non-profit organization.
American Thrombosis and Hemostasis Network	Chair of research committee	Unpaid	ongoing	Not a COI. ATHN is a non-profit organization.
American Society of Hematology	Committee member	Unpaid	ongoing	Not a COI. ASH is a non-profit organization
Bloodworks Northwest	Staff; small part of support for organization comes from corporate donations	Paid	ongoing	Not a COI. Bloodworks NW is nonprofit organization that supplies blood products to hospitals in the Northwest United States and supports the Bloodworks Research Institute. The organization will not be directly affected by recommendations about how to diagnose VWD.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I co-authored a textbook chapter on VWD in the 3rd edition of Consultative Hemostasis and Thrombosis and have a pending article for the 4th edition. In that chapter we present available testing and discuss published pro and cons of different assays.

I wrote an editorial commenting on manuscripts that described new methods for diagnosing VWF in 1995 and 2016. The 2016 was an Inside Blood: Konkle BA. Defining von Willebrand disease. Blood. 2016;127:2373-2374.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

I see patients in the Washington Center for Bleeding Disorders including patients with von Willebrand disease. I am the medical director for our clinical hemostasis laboratory which performs VWD testing. I receive some salary support as laboratory director.

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

I answered no but wanted to give an explanation. If the guidelines recommend no testing for VWD that would adversely affect the test volume in our hemostasis lab. If different testing than what we are currently doing is recommended, that would be unlikely to adversely affect the laboratory revenue, as we would change the testing to what is recommended. Thus given that it is unlikely that the guidelines will advise no testing, I think it is unlikely they would adversely affect the institution.

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

As a senior member and Associate Chief Scientific Officer at my institution, and given my experience in this field, I feel confident my institution would support me.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty?

Patients with disorders of coagulation, including von Willebrand disease.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain:

I order laboratory evaluations for von Willebrand disease.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Gilead Sciences	Consultation on effect of HIV drug on platelets, began in January 2018, no activity since March 2017.	7/09/2018	Not a COI. Gilead Sciences does not market any products that can be affected by the guidelines.
Shire/Takeda	Dr. Konkle confirmed that she withdrew from both (Part A, page 4).	7/09/2018	Not a COI. Dr. Konkle has withdrawn from farther activities on the Shire boards.
Spark Therapeutics	Consulting, Gene therapy advisory board 5/18 Research, Gene therapy trial for hemophilia A.	7/09/2018	Not a COI. Spark Therapeutics does not market any products that can be affected by the guidelines.
Pfizer	Research on Gene therapy trial for hemophilia B.	7/09/2018	Indirect COI. Pfizer markets recombinant factor VIII and factor IX for the treatment of Hemophilia A and B. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Pfizer also markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer markets contraceptive estrogen products that could be used in the

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			management of VWD symptoms in women.
Seattle Genetics	Advisory Board on hemostatic effects of a cancer drug, one day activity in August 2018.	9/17/2018	Not a COI. Seattle Genetics does not market any products for the diagnosis or treatment of VWD
N/A	World Federation of Hemophilia (WFH), elected her to the WFH Board of Directors through June 2022	9/17/2018	Not a COI.
CSL Behring	Honoraria and travel via for an activity with the Foundation for Women and Girls with Blood Disorders.	9/26/2019	Direct COI. CSL Behring makes desmopressin which can be used to treat and diagnose VWD.
Hoffmann La-Roche (Roche)	Consulting and speaking, travel fees, ongoing.	9/26/2019	Direct COI. As noted above, Roche markets a product for the diagnosis of VWD. Roche owns Hoffmann-La Roche.
Octapharma	Food and beverage 12/2018 and 05/2019.	9/26/2019	Indirect COI. As noted above, Octapharma markets a product for the treatment of VWD.
Pfizer	Consulting and travel, ongoing.	9/26/2019	Indirect COI. As noted above, Pfizer markets a product for the treatment of VWD.
Sanofi	Consulting and travel, 2018.	9/26/2019	Indirect COI. Sanofi owns Bioverativ, which markets a factor VIII product that may be affected by the guidelines.
CSL Behring	Update Member of independent data	11/22/2019	Not a COI. Dr. Konkle is no longer active on this board.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	monitoring committee for a FIX product		
Merck	Update See part A Spouse's equity ownership. No longer a direct COI.	11/22/2019	Not a COI. Merck markets an estrogen contraceptive product that could be used in the management of VWD symptoms in women. However, they are marketed to a large population and VWD is a rare disease, any effects on the company are expected to be negligible and do not present a conflict of interest.
Pfizer	Consultant on gene therapy in healthcare, June 2019.	12/03/2019	Indirect COI. See above.
Sanofi	Advisory Committee on hemophilia A therapy, June, 2019	12/03/2019	Not a COI. See above.
Sigilon Therapeutics	Consultant on protocol development for a new treatment in hemophilia – ongoing	12/03/2019	Not a COI. Sigilon Therapeutics makes products focused on contain engineered human cells to treat patients with chronic disease. Currently this company does not market any products for the treatment or diagnosis of VWD.
Spark Therapeutics	Advisory Board on gene therapy, December 2019	12/03/2019	Not a COI. See above.
Shire/Takeda	Update 12/03/2019 See part B.	12/03/2019	Not a COI. Dr. Konkle is no longer the PI for this study as it ended due to low recruitment.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	Site PI - Gene therapy trial in hemophilia		
Shire/Takeda	PI: Investigator-initiated grant (CompSeq) to study genetic analysis of VWD and associated genes. Expected end date, April 2020	12/03/2019	Indirect COI. As noted above, Shire/Takeda markets products for the treatment of VWD that may be affected by the guidelines.
Shire/Takeda	Site PI: Gene Therapy in hemophilia B study in long term follow up, Expected end date, June 2031	12/03/2019	Indirect COI. See above.
Pfizer	Site PI: Gene therapy lead-in trial in hemophilia B	12/03/2019	Indirect COI. See above.
Sigilon	Site PI: Cellular therapy for hemophilia A	12/03/2019	Not a COI. See above.
Spark Therapeutics	Site PI: Observational trial for hemophilia A gene therapy	12/03/2019	Not a COI. See above.
uniQure	Site PI: Gene therapy trial in hemophilia B	12/03/2019	Not a COI. See above.
N/A	Update See part B Chair of Research Committee for the American Thrombosis and Hemostasis Network	12/03/2019	Not a COI. This activity ended in 2018.
Bioverativ Therapeutics	Consulting and travel, 2019.	7/15/2020	Indirect COI. Bioverativ markets recombinant factor VIII. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 1/29/18; Castano, Kunkle, 3/22/18; Djulgovic, 5/04/2018	Yes	Yes	<p>Dr. Konkle has direct financial COIs with Roche, this was managed through recusal (equity ownership, paid consulting for development of a new impact scale in hemophilia) and Merck (equity ownership). These companies may be directly or indirectly affected by the guidelines.</p> <p>Dr. Konkle also has potential indirect financial COIs with companies that may be affected by the guidelines: CSL Behring (paid member of a data monitoring committee for a factor IX product); Bioverativ (site PI for a clinical trial of a longer acting factor VIII product); Shire (site PI for a gene therapy trial in hemophilia, ended 8/2018).</p>
Castano, 7/27/2018	Yes	Yes	<p>Dr. Konkle disclosed activities with Gilead Sciences (consulting for HIV medication), and Spark Therapeutics (gene therapy research for hemophilia A), which do not constitute conflicts of interests, as these two companies do not market products that can be affected by the guidelines. Dr. Konkle also disclosed that she is no longer participating in Advisory Board activities with Shire (Part A) a company that markets products that may be affected by the guidelines.</p> <p>Dr. Konkle disclosed that she is participating in a Pfizer research study for gene therapy to treat hemophilia A. This may be an indirect conflict of</p>

			interest, as Pfizer is a company that market products that may be affected by the guidelines.
Castano, 9/27/2018	Yes	Yes	Dr. Konkle disclosed that she has been elected to the WFH Board of Directors.
Castano, 11/25/2019	Yes	Yes	Dr. Konkle has new direct conflicts of interest with Roche, through Hoffman La-Roche (Consulting and travel) and with CSL Behring (Consulting). These two conflicts were managed through refusal. There are two updates to Dr. Konkle's DOI form, her spouse's relationship with Merck is no longer considered a direct conflict of interest because the effect that the guideline questions may have on this company's hormonal product may be negligible. Dr. Konkle's research relationship with Bioverativ is no longer considered an indirect financial conflict because this company's products will not be addressed by any of the guideline questions.
Castano, 12/03/2019	Yes	Yes	New Disclosures: Dr. Konkle disclosed two new indirect financial conflicts with Pfizer (Consulting and PI of a gene therapy study). She also disclosed three new indirect financial conflicts with Shire Takeda (PI for a study of genetic analysis of VWD, Site PI for an epidemiological study of AAV immunity and site PI for a long-term study of hemophilia B).
Castano, 7/15/2020	Yes	Yes	On July 15, 2020 Dr. Konkle confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Genentech/Roche	Consulting on development of new impact scale in hemophilia	11/2017	Direct COI. Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche also markets a product for the prophylactic treatment of bleeding episodes in patients

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
			with hemophilia A with factor VIII inhibitors.
Roche	Equity Ownership	11/2017	Direct COI. See part A.
Merck	Equity Ownership	11/2017	Direct COI. Merck markets an estrogen contraceptive product that could be used in the management of VWD symptoms in women. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment. See part B
CSL Behring	Honoraria and Travel	9/26/2019	Direct COI
Hoffmann La-Roche (Roche)	Consulting	9/26/2019	Direct COI.

Other Notes

Dr. Konkle is a hematologist. She is the Associate Chief Scientific Officer at Bloodworks Northwest, a non-profit organization that supplies blood products to hospitals in the Northwest United States. The organization receives some industry funding. In her clinical practice, Dr. Konkle sees patients with coagulation disorders, including VWD, at the Washington Center for Bleeding Disorders. She is the medical director for the clinical hemostasis laboratory, which performs VWD testing. The laboratory could be affected by recommendations against VWD testing but not by recommendations about which tests to use.

She co-authored a textbook chapter on VWD in the 3rd edition of Consultative Hemostasis and Thrombosis and has a pending article for the 4th edition, which discusses testing for VWD. She also wrote an editorial commenting on manuscripts that described new methods for diagnosing VWF in 1995 and 2016, Blood: Konkle BA. Defining von Willebrand disease. Blood. 2016;127:2373-2374

Dr. Konkle reports unpaid leadership positions in non-profit organizations, including Foundation for Women and Girls with Blood Disorders (board member) and World Federation of Hemophilia (WFH) (Board of Directors).



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Advisory committee for fibrinogen	ongoing	Not a COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin, all products used to treat VWD. The company could be indirectly affected by recommendations that increase or decrease the number of patients who are diagnosed with VWD and subsequently treated. However, Dr. McLintock has agreed to avoid direct financial relationships with companies that could

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			be affected by the guidelines for the duration of guideline development, starting from the time of her appointment to the guideline panel.
AMGEN	Speaker fee for meeting on ITP	March 31 2016	Not a COI. Amgen does not market any products for the diagnosis or treatment of bleeding disorders.
CSL Behring	Funding for PPH study: Investigator initiated study looking at fibrinogen concentrate in PPH	ongoing	See note in Part B below.
Bayer	Speaker fee for talk on venous thromboembolism	July 2016	Not a COI. This relationship concluded prior to appointment to the guideline panel, and Dr. McLintock has agreed to avoid direct financial relationships with companies that could be affected by the guidelines for the duration of guideline development.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Investigator initiated study: placebo controlled randomized feasibility study of ROTEM guided fibrinogen concentrate replacement in women with severe PPH. CSL Behring provide funding for fibrinogen concentrate.	Member of local study team	ongoing	Indirect COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. As described in Part A, the company could be indirectly affected by diagnostic recommendations. Dr. McIntock does not have a leadership role in this research, and the subject of the research is related but not specific to VWD.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

No

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

No

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

No

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would anticipate that I would be strongly supported by my institution

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

Yes

If yes, what is your primary specialty or subspecialty?

Haematology and Obstetric Medicine

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

Yes

If yes, please explain:

Approach to diagnosis and patient care would be affected

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	Dr. McLintock serves as the International Society on Thrombosis and Haemostasis (ISTH) President for 2018-2020.	8/31/2018	Not a COI. ISTH is one of three collaborators working with ASH on these guidelines.
CSL Behring	Update 1/08/2019 See part A Advisory committee for fibrinogen – Dr. McLintock’s participation in this committee ended in 2016.	1/08/2019	Not a COI.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/17; Kunkle 3/8/17; Djulgovic, Cheung, Holter- Chakrabarty, 3/09/2018	No	Yes	Dr. McLintock reports recent direct payments from CSL Behring. CSL Behring makes desmopressin that can be used in the diagnosis of VWD and could be affected by recommendations about diagnosis of VWD. She also has a non-leadership role on research about fibrinogen concentrate for women with severe postpartum hemorrhage, funded by CSL Behring. All funding goes to her institution. Dr. McLintock has agreed to avoid direct financial relationships with companies that could be affected by the guidelines for the duration of guideline development.
Castano, 9/27/2018	No	Yes	New Disclosure: Dr. McLintock serves as the 2018-2020 President of the International Society on Thrombosis and Haemostasis (ISTH). See part D.
Castano, 1/8/2019	No	Yes	New Disclosure: Dr. McLintock confirmed that an advisory board activity with CSL Behring, see part A of this form, ended in early 2016.
Castano, 7/21/2020	No	Yes	On 7/21/2020 Dr. McLintock confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. McLintock is a specialist in hematology and obstetric medicine. In her clinical practice, she diagnoses and cares for patients with VWD.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL-Behring	Travel Support to Advisory Board	Oct 2016	Not a COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Mcrae has agreed to avoid direct financial conflicts for the duration of the guideline development process.
CSL-Behring	Travel support to Isth	June 2017	Not a COI. See above.
NovoNordisk	Payment for organization of educational meeting	July 2016	Not a COI. Novo Nordisk markets recombinant factor VIIa for bleeding in patients with severe disease who are not responsive to other treatments and a recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Mcrae has agreed to avoid direct financial conflicts for the

Company	Description	End Date	For ASH Internal Use
			duration of the guideline development process.
Roche	Travel Support to Advisory Board	July 2017	Not a COI. Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand factor. Outside the US, Roche markets products for the prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors. This activity concluded prior to initiation of the guidelines, and Dr. Mcrae has agreed to avoid direct financial conflicts for the duration of the guideline development process.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Indepent investigator driven research project establishing prevalence of joint arthropathy in patients with severe haemophilia within Australia.	Overall PI	Ongoing	Indirect COI. As noted above, CSL Behring markets products that could be affected by the guidelines.
Biogen	Phase III trial of therapeutic agent for haemophilia A	Local PI	Mar 2018	Not a COI. Bioverativ, formerly part of Biogen, was sold to Sanofi in January 2018. Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment. However, this activity concluded prior to initiation of the guidelines, and Dr. McRae has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Biogen	Phase III trial of therapeutic agent for Haemophilia B	Local PI	Mar 2018	Not a COI. See above.
Baxter / Shire	Phase III trial of therapeutic agent for haemophilia A	Local PI	Mar 2018	Not a COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Dr. Mcrae has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Roche	2 Phase III trials for therapeutic agent for haemophilia A	PI	Ongoing	Indirect COI. As noted above, Roche markets products that could be affected by the guidelines.
Acceleron / Celgene	Phase III trial of therapeutic agent for thalassaemia	PI	Ongoing	Not a COI. Acceleron and Celgene do not market products that can be used in the treatment or diagnosis of VWD.
La-Jolla Pharmaceuticals	Phase III trial for a thalassemia study examining a novel agent looking at stimulating red cell production.	PI	Ongoing	Not a COI. La Jolla Pharmaceuticals does not market products that can be used in the treatment or diagnosis of VWD.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I was involved in the publication of a paper that commented on the comparative performance of a new assay for the diagnosis of von Willebrand disease.

Haemophilia. 2016 May;22 (3):e200-7.

Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
National Blood Authority - Australia	Observational Research Patients with bleeding disorders – via Australian Bleeding Disorder Registry	Chair of Steering Committee	Ongoing

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No impact.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

Haematology sub-specializing in bleeding disorders.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain:

I prescribe treatment for patients with von Willebrand's disease and am involved in the supervision of a diagnostic laboratory for that process samples from patients with bleeding disorders.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
 Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	Dr. Mcrae moved in early 2020 from Adelaide to Tasmania, Australia.	1/14/2020	Not a COI.
Roche	Virtual talk on the clinical presentation for Roche on “Use of emicizumab in haemophilia A patients without inhibitors”.	7/8/2020	Direct COI. Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche also markets a product for the prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 6/04/2018; Holter-Chakrabarty, 6/12/2018	No	Yes	<p>Dr. Mcrae has two indirect conflicts of interest with companies that can be affected by the guidelines, CSL Behring (Overall PI for a research project on the prevalence of joint arthropathy in patients with severe hemophilia) and Roche (Local PI for 2 Phase III trials for therapeutic agent for hemophilia A).</p> <p>Dr. Mcrae reports several recent paid activities with companies that can be affected by the guidelines (CSL-Behring, NovoNordisk, Roche, and Shire). However, he has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.</p>
Castano, 7/15/2020	Yes	Yes	<p>On July 8, 2020 Dr. Mcrae disclosed a paid virtual speaking activity with Roche, which constitutes a direct financial conflict, because Roche makes a test that may be affected by the guidelines. However, this disclosure occurred after the panel had agreed on recommendations; therefore, Dr. Mcrae was not recused. On July 15, 2020 Dr. Macrae confirmed all information on this form.</p>

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Mcrae is a hematologist specializing in bleeding disorders. In his clinical practice he prescribes treatment for patients with von Willebrand's disease and he is involved in the supervision of a diagnostic laboratory that processes samples from patients with bleeding disorders.

Dr. Mcrae co-authored a publication that comments on the comparative performance of a new assay for the diagnosis of von Willebrand disease. *Haemophilia*. 2016 May;22(3):e200-7. doi: [10.1111/hae.12937](https://doi.org/10.1111/hae.12937).

He currently serves as Steering Committee Chair for the Observational Research of Patients with Bleeding Disorders group of the Australian Bleeding Disorder Registry, at the National Blood Authority of Australia.

Dr. Mcrae moved in early 2020 from Adelaide Australia to Launceston Tanzania.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
9,678,089 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	current	Potential Direct COI. Dr. Montgomery was involved in the discovery of these technologies, which the BloodCenter of Wisconsin is licensed to use. Through the licensing agreement, Dr. Montgomery and his lab earn royalties. It is unclear at this time if these methods and kits may be affected by the guidelines.
9,046,535 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	Current	
8,865,415 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	Current	
8,318,444 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	Current	
8,163,496 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	Current	
9,678,089 BloodCenter of WI	Methods and kits for measuring von Willebrand factor	Current	

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Med advisory	ongoing	Indirect COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
CSL Behring	Med advisory	ongoing	Direct COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. Desmopressin is also used to diagnose VWD during the desmopressin challenge. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Novo	Grant review	ongoing	Indirect COI. Novo Nordisk markets a recombinant factor for bleeding in patients with severe disease who are not

Company	Description	End Date	For ASH Internal Use
			responsive to other treatments and a recombinant factor VIII for treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Hema Biologics	Med advisory	2017	Not a COI. Hema Biologics has one pipeline product in Phase 3, for the treatment of hemophilia A and B in patients with inhibitors to factor VIII or IX. They also may have an investigational product for the treatment of severe VWD. They do not currently market any products indicated for the diagnosis or treatment of VWD. This activity concluded prior to appointment to the guideline panel and Dr. Montgomery has agreed to avoid direct financial conflicts with affected companies for the duration of guideline development process.
Octapharma	Med Advisory	2017	Not a COI. Octapharma markets a VWF replacement therapy for the treatment of patients with VWD. They also market a recombinant factor VIII product for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to appointment to the guideline panel and Dr. Montgomery has agreed to avoid direct financial conflicts with affected companies for the duration of guideline development process.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novo	Provided rat model of hemophilia – research not supported by Novo	Investigator	ongoing	Indirect COI. As noted above, Novo Nordisk markets products that may be used in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Shire	rVWF to use in rat and mouse models of hemophilia and VWD	Investigator	ongoing	Indirect COI. As noted above, Shire markets products that may be used in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
NHF/Shire	Clinical Hemophilia Fellowship to Jessica Garcia	One of mentors	June 30, 2018	Indirect COI. As noted above, Shire markets products that may be used in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
National Hemophilia Foundation MASAC	Medical advisory Board MASAC	unpaid	Ongoing	Not a COI. NHF is not a for-profit company.
Great Lakes Hemophilia Foundation	Board Member	unpaid	Ongoing	Not a COI. Great Lakes Hemophilia Foundation is a chapter of NHF and is not a for-profit company.
BloodCenter of WI	Investigator employee	Paid employee	Ongoing	Not a COI. BloodCenter of WI is not a for-profit company.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? I was on previous Guidelines Committee and was co-author of its publications. I have supported those guidelines recommendations in academic talks that I have given.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NIH	PPG Study of the molecular and clinical biology of VWD	Program Director Project Leader Core Leader	ongoing
NIH	R01 on comparative effectiveness in the diagnosis of VWD	PI	ongoing
NIH	R01 on the relationships between FVIII and VWF	PI	ongoing

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain: I have given talks on diagnosis of VWD where I am not paid but BloodCenter is paid by CSL or Shire for training of staff at those companies

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain: BloodCenter oversees the provision of products to treat VWD or Hemophilia and its diagnostic Lab does national level testing for VWD. I am not directly involved in these activities and do not receive any direct salary based on these activities.

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I think that my institution would strongly support any academic implementation of guidelines for testing or treatment.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
NHF	Prior guidelines	MASAC member
BCSEW/Versati	Support development of academic guidelines.	employee
Medical College of WI	Support development of academic guidelines.	Unpaid full-time faculty member

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty? Pediatric hematology. I do not see patients in clinic but I do give advice to patients and other physicians through my work on VWD.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain: Make recommendations to other physicians on diagnosis of VWD

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	After reviewing the final PICO questions ASH staff and Dr. Montgomery determined that it will be adequate for him to recuse from questions 3 and 5 which address technologies similar to those in his patents devolved for Versiti BloodCenter of Wisconsin.	10/03/2018	Direct COI. Patents created for Versiti BloodCenter of Wisconsin that can be affected by the guidelines, see part A.
Bioverativ/Sanofi	Educational Symposium	4/16/2019	Indirect COI. Sanofi owns Bioverativ, which markets a factor VIII product that may be affected by the guidelines.
Novo Nordisk	Update Grant review – ongoing	11/27/2017	Indirect COI. See above.
Novo Nordisk	Update PI Provided rat model of hemophilia – research not supported by Novo	11/27/2017	Indirect COI. See above.
CSL Behring	Travel to Arizona Hemophilia Foundation Meeting March 2018.	9/9/2019	Indirect COI. Although the meeting was sponsored by CSL Behring, payments were made through the Arizona Hemophilia Foundation and not

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			directly to Dr. Montgomery.
Novo Nordisk	Consulting March 2018 Food and beverage, July 2019	9/9/2019	Indirect COI. See above.
Octapharma	Honoraria and travel to attend the VWD Connect Foundation meeting in October 2018.	9/9/2019	Indirect COI. Octapharma is a human proteins manufacturer that markets a VWF replacement therapy (Wilate) for the treatment of patients with VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Sanofi	Research to establish the importance of VWF in delivering FVIII to the local evolving thrombus.	10/25/2019	Indirect COI. Sanofi owns Bioverativ, which markets a factor VIII product that may be used along with factor VWF for the treatment of VWD.
N/A	Update see part B The relationship of employment with Versiti BloodCenter of Wisconsin is updated to reflect an indirect financial conflict.	1/15/2020	Indirect COI. Versiti BloodCenter of Wisconsin is not a for-profit company, which has proprietary test for VWD and could be affected by these guidelines.
Sanofi US Services and Sanofi Aventis	Consulting, travel, food and beverage.	7/3/2020	Indirect COI. See above.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
<p>Senerth, 12/12/2017;</p> <p>Castano, 03/26/2018;</p> <p>Djulgovic, 6/01/2018</p>	Maybe	Yes	<p>Dr. Montgomery has one potential direct financial COI as he has received and may continue to receive royalties for several VWD related patents, owned by the BloodCenter of Wisconsin, which he helped developed.</p> <p>He has indirect financial conflicts with Novo Nordisk (Investigator, rat model for hemophilia research) and Shire (Investigator, rVWF to use in rat and mouse models of hemophilia and VWD; and mentorship support to a Clinical Hemophilia fellow).</p> <p>He serves as a paid medical advisor at both Shire and CSL Behring, these activities are potential indirect COIs as these companies may be indirectly affected by the diagnosis panel guideline.</p>
Castano, 10/03/2018	Yes	Yes	<p>As noted above, Dr. Montgomery is a paid advisor with CSL Behring. CSL Behring makes desmopressin which is used for both management and diagnosis of VWD. This conflict was managed through recusal.</p> <p>In addition, Dr. Montgomery owns several patents with similar diagnosis technology that can be affected by the guidelines. Please see parts A and D for details. This conflict was managed through recusal.</p>
Castano, 11/21/2019	Yes	Yes	<p>On September 2019, Dr. Montgomery disclosed activities that constitute indirect conflicts of interest with Octapharma, CSL Behring, and Novo Nordisk. On October 2019, Dr. Montgomery</p>

			disclosed an activity with Sanofi, which constitutes an indirect financial conflict. Please see part D for details.
Castano, 7/14/2020	Yes	Yes	On July 3, 2020 Dr. Montgomery confirmed all the information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
CSL Behring	Medical Advisor	2017	Direct COI.
N/A	Owns Several Patent Royalties – See part A and part D	2017	Direct COI.

Other Notes

Dr. Montgomery is a pediatric hematologist and professor within the Medical College of Wisconsin and a senior investigator at the Blood Center of Wisconsin. He does not see patients in the clinic, but he advises patients and other physicians about VWD. The Blood Center of Wisconsin has proprietary tests for VWD and could be affected by these guidelines, depending on the tests addressed by the guideline recommendations.

Dr. Montgomery is the PI for three NIH funded studies about VWD and VWF (see above).

He was involved in developing prior guidelines on bleeding disorders for NHF. He has continued to support the guidelines through academic presentations.

He has given talks on the diagnosis of VWD with the purposes of training staff at Shire and CSL Behring. He is not paid, however CSL Behring and Shire paid the BloodCenter of Wisconsin for these talks. Although, the BloodCenter oversees the provision of products to treat VWD or Hemophilia and its diagnostic lab does national level testing for VWD, DR. Montgomery is not directly involved in these activities and does not receive any direct salary based on them. The BloodCenter could be affected by recommendations against VWD testing but not by recommendations about which tests to use.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I suspect they will be supportive but I don't really know.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Nephrologist

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Kunkle, 3/16/18; Lottenberg, 5/10/2018	No	No	Dr. Mustafa has no direct or indirect conflict of interests with companies that can be affected by the guidelines.
Castano, 7/31/2020	No	No	On July 31, 2020 Dr. Mustafa confirmed all information on this from.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Mustafa is a nephrologist and methodologist. In her clinical practice, she does not diagnose or treat patients with von Willebrand disease. Under an agreement between ASH and the University of Kansas Medical Center, she is leading systematic reviews of available evidence for these guidelines.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Leo Pharma	Speakers Bureau	20/11/17	Not a COI. Leo Pharma does not market any products for the diagnosis or treatment of bleeding disorders. This activity concluded prior to initiation of the guidelines, and Dr. O’Donnell has agreed to avoid direct financial conflicts for the duration of the guideline development process.
LFB (France)	Speakers Bureau	6/10/17	Not a COI. LFB markets a human plasma-derived VWF concentrate for the treatment of VWD. At the time of review, this therapy is only available in Europe. This activity concluded prior to initiation of the guidelines, and Dr. O’Donnell has agreed to avoid direct financial conflicts for the duration of the guideline development process.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer (cofunded by Science Foundation Ireland National Research Funding Body sfi.ie)	Developing long acting FVIII therapies for patients with Haemophilia A.	PI	Ongoing – ends 31/8/17	Not a COI. Pfizer markets a recombinant factor VIII and factor IX. for the treatment of Hemophilia, A and B. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Pfizer also markets a tranexamic acid to aid in the formation of clots to treat bleeding. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer also markets estrogen products that could be used in the management of VWD symptoms in women This research study concluded prior to initiation of the guidelines.
Shire (cofunded by Science Foundation Ireland National Research Funding Body sfi.ie)	Personalized treatment for Haemophilia	PI	Ongoing – ends 31/8/21	Indirect COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.

Paid and Volunteer Activities for Organizations Supported by Industry

- Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

We currently have a paper in press in *Blood* (Lavin M *et al*) that presents the results of the Low von Willebrand factor Ireland Cohort study.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

The National Coagulation Centre in Dublin has an established international reputation. Consequently, this would not be an issue.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Primary specialty – Hematology

Subspecialty – Thrombosis and Hemostasis

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I am involved as a Consultant Hematologist in the diagnosis and treatment of patients with bleeding disorders including von Willebrand disease.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/17; Castano, Kunkle, 3/20/18; Djulgovic, 5/07/2018	No	Yes	Dr. O'Donnell has an indirect COI with Shire (PI, research on hemophilia), a company that markets treatments for VWD and therefore may be indirectly affected by the guidelines. Dr. O'Donnell reports one recent paid activity with LBF, a company that may be affected by the guidelines. Dr. O'Donnell has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Castano, 7/15/2020	No	Yes	On July 5, 2020 Dr. O'Donnell confirmed all the information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. O'Donnell is a hematologist. He specializes in thrombosis and hemostasis. In his clinical practice he is involved in the diagnosis and treatment of patients with bleeding disorders including von Willebrand disease.

Dr. O'Donnell is a co-author on the Low VWF Ireland Cohort study, reported in *Blood* 2017 130:2344-2353, <http://www.bloodjournal.org/content/130/21/2344?sso-checked=true>.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: Bleeding symptoms and bloodwork should both be taken into consideration when diagnosing von Willebrand Disease.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

- Column 1 Name the entity funding the research.
- Column 2 Describe the research project.
- Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
- Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	New Employment Education Program Coordinator – National Hemophilia Foundation, NHF	May 15, 2018	Not a COI.
N/A	Ms. Scappe was promoted to Education Specialist effective January 1, 2020 at NHF	July 6, 2020	Not a COI.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 3/27/2018; Kunkle, 4/2/2018; Cheung, 5/15/2015	No	No	Ms. Scappe does not have any direct or indirect financial COI with companies that could be affected by these guidelines.
Castano, 7/15/2020	No	No	On July 6, 2020 Ms. Scappe confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Ms. Scappe is serving as a patient representative on the guideline panel.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

XX No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

XX No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

XX No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

XX Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Advisory board	10/2017	Not a COI. Shire markets recombinant von Willebrand Factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. This activity concluded prior to initiation of the guidelines, and Dr. Sidonio has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.
CSL Behring	Advisory board	08/2017	Not a COI. CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Sidonio has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.
Grifols	Advisory board	06/2017	Not a COI. Grifols markets an antihemophilic factor/von Willebrand factor complex indicated for the treatment of VWD in patients for whom desmopressin is either ineffective or contraindicated. This activity concluded prior to initiation of the guidelines, and Dr. Sidonio has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

XX No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bioverativ/ Biogen	Pilot study to evaluate the utility of Eloctate and Alprolix in the treatment of heavy menstrual bleeding in adult hemophilia A and B carriers/ Study only involves hemophilia A and B carriers.	PI	09/2019	Indirect COI. Bioverativ was sold by Biogen to Sanofi in January 2018. Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
Grifols/ Kedrion	Prospective study to evaluate the prevalence and incidence of FVIII	PI	1/2020	Indirect COI. Grifols/Kedrion markets an antihemophilic von Willebrand factor complex indicated for the treatment of

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	inhibitors in hemophilia A patients in Mexico City. Study only involves severe and moderate hemophilia A patients			VWD in patients for whom desmopressin is either ineffective or contraindicated. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Blood CME	Speaker online and at university locations on general VWD and hemophilia topics	Paid	10/2017	Not a COI. BloodCME is a medical education company. This was an ACCME-accredited activity, and Dr. Sidonio did not receive any direct payments from industry.
NHF	Speaker online and at annual meetings on general VWD and hemophilia topics	Paid	8/2017	Not a COI. The National Hemophilia Foundation is not a for-profit organization.
HFA	Speaker at annual meetings on hemophilia topics	Paid	6/2017	Not a COI. The Hemophilia Federation of America is not a for-profit organization.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Wrote an article published in Blood with Dr. Anne Neff on the management of VWD. It summarized the current recommendations on management of VWD discussing all therapeutic options with no preference chosen.

Sidonio RF, Neff A. Management of VWD. Hematology 2014.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

XX No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

XX No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

XX No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

XX No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I am funded by the Hemophilia of Georgia and on a no-cost extension for an HTRS mentored research award to end in July 2018 that was funded by Baxter to HTRS to administer. My research for both of these foundation grants is on the bleeding tendency of hemophilia A and B carriers and not VWD. I do not anticipate any strong reaction by being involved in these guidelines, as I am involved in the bleeding disorder community already in multiple leadership organizations based on my research in women with bleeding disorders. My Chief and mentor have not identified any concern if my involvement in these guidelines generated controversy and they do not plan on changing their support for my career.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

XX Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
HFA	Medical advisor	I am one of the medical advisors that they request input on medical content online and provide input for their meetings.
NHF	I am currently a member of MASAC and a member of the VWD subcommittee	I was recently selected to be a board member for MASAC and have been involved in the VWD subcommittee chaired by Bob Montgomery and Veronica Flood
HTRS	Board member	I was elected as a board member and participate in planning meetings, grant reviews and policy

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

I am a pediatric hematologist and the Clinical Director and Director of Clinical Research of the Hemophilia Treatment Center at Children’s Healthcare of Atlanta. Currently I have dedicated 25% to clinical work, 15% for administrative work and 60% to clinical research.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain: I am the Director of my HTC and do lead the Women’s Bleeding Disorder Clinic and am involved in QI initiatives. I am leading an initiative to standardize our strategy to diagnose and manage adolescent girls with heavy periods who often end up having VWD. This is a non-industry funded study and using my own personal start up funds to pay for this prospective QI

project. I do not have full control of the management decisions and am 1 of 4 hemostasis providers in our hospital who all retain independent control of their patients with VWD.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Octapharma	PI, Wilate prophylaxis clinical trial	9/12/2018	Indirect COI Octapharma markets a VWF replacement therapy for the treatment of patients with VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations on diagnosis that increase or decrease the number of patients who are eligible to use a given treatment.
N/A	CME activity sponsored by CDC on improving Outcomes for VWD. https://www.impactedu.net/bleeding/	9/10/2019	This was an ACCME-accredited activity, and Dr. Sidonio did not receive any direct payments from industry.
Bayer	Consulting and travel.	9/12/2019	Not a COI. Bayer is a pharmaceutical company that markets hormonal products that can be used to treat women with VWD. However, they are market to a large population and VWD is a rare disease, any effects on the company are expected to be negligible and do not present a conflict of interest.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Biomarin	Consulting, travel, food and beverage, ongoing.	9/12/2019	Not a COI. BioMarin is a biotechnology company that markets products for rare genetic diseases that do not include bleeding disorders. They do not have any marketed or pipeline products indicated for the diagnosis or treatment of VWD.
CSL Behring	Speaking fees and travel.	9/12/2019	Direct COI. CSL Behring markets desmopressin that can be used to diagnoses VWD in what is known as the desmopressin trial.
Roche via Hoffmann-La Roche and Genentech	Consulting and speaking fees, ongoing.	9/12/2019	Direct COI. Roche is a pharmaceutical and diagnostic company that markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche owns both Hoffmann-La Roche and Genentech.
Grifols	Consulting and travel.	9/12/2019	Indirect COI as noted above, Grifols markets products for the treatment VWD that may be indirectly affected by recommendations made by diagnosis panel.
Kendrion	Consulting and travel.	9/12/2019	Not a COI. Kedrion does not have any marketed or pipeline products indicated for

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			the diagnosis or treatment of VWD.
Novo Nordisk	Consulting and travel, ongoing.	9/12/2019	Indirect COI. Novo Nordisk markets recombinant factor VIII. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
Octapharma	Consulting and travel, ongoing.	9/12/2019	Indirect COI. See above.
Pfizer	Consulting and travel, ongoing.	9/12/2019	Indirect COI. Pfizer makes tranexamic acid to aid in the formation of clots to treat bleeding in patients with VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations made by the diagnosis panel.
Shire	Consulting and travel, ongoing.	9/12/2019	Indirect COI. As noted above, Shire markets products to treat VWD. Companies that market products for the treatment of VWD may be indirectly affected by recommendations made by the diagnosis panel.
Spark Therapeutics	Consulting, food and beverage, ongoing.	9/12/2019	Not a COI. Spark therapeutics does not make any products indicated for the treatment of VWD.
Pfizer	Speaking and travel, ongoing.	10/19/2019	Indirect COI. See above.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Aptevo Therarapeutics	Consulting	7/15/2020	Not a COI. Aptevo is not an affected company.
Bioverativ	Consulting	7/15/2020	Indirect COI. Bioverativ markets recombinant factor VIII. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
Eagle Pharmaceuticals	Consulting	7/15/2020	Not a COI. Eagle is not an affected company.
Genzyme Corporation	Consulting	7/15/2020	Indirect COI. Genzyme is owned by Sanofi. Sanofi owns Bioverativ, which markets a factor VIII product that may be affected by the guidelines.
Jazz Pharmaceuticals	Food and beverage	7/15/2020	Not a COI. Jazz is not an affected company.
Sanofi-Aventis	Consulting, food and beverage	7/15/2020	Indirect COI. Sanofi owns Bioverativ, which markets a factor VIII product that may be affected by the guidelines.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease
----------------------------	--

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/12/17; Castano, 03/22/18; Kunkle, 4/2/18; Lottenberg, 5/10/2018	No	Yes	<p>Dr. Sidonio has two indirect financial conflicts with companies that could be indirectly affected by these guidelines: Bioverativ (owned by Sanofi) (Overall PI, research on treatments for heavy menstrual bleeding in women with hemophilia) and Grifols/Kedrion (Overall PI, study to evaluate the prevalence and incidence of FVIII inhibitors in hemophilia patients in Mexico City).</p> <p>Dr. Sidonio reports recent paid activities with Shire (Advisory Board), CSL Behring (Advisory Board), and Grifols (Advisory Board), but he has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.</p>
Castano, 9/26/2018	No	Yes	<p>New Disclosure: Dr. Sidonio reports an additional indirect conflict with Octapharma, a company that may be affected by the VWD management guidelines. On 9/12/2018 Dr. Sidonio disclosed a new activity with Octapharma, he will be a PI on a Wilate prophylaxis clinical trial.</p>
Castano, 11/22/2019	Yes	Yes	<p>Dr. Sidonio disclosed several consulting and speaking activities with pharmaceutical companies that market products for the treatment of VWD including Octapharma, Shire, Grifols, and Pfizer, these activities are indirect financial conflicts. He reported additional direct conflicts with Roche (via Genentech and Hoffman-LaRoche) and CSL Behring, both of which make diagnostic products for VWD, these were managed through recusal.</p>

Castano, 7/15/2020	Yes	Yes	On July 2, 2020 Dr. Sidonio confirmed all information on this form.
-----------------------	-----	-----	---

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Roche via Hoffmann-La Roche and Genentech	Consulting and speaking fees.	9/12/2019	Direct COI. Roche is a pharmaceutical and diagnostic company that markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US.
CSL Behring	Speaking fees and travel.	9/12/2019	Direct COI. CSL Behring markets desmopressin that can be used to diagnoses VWD in what is known as the desmopressin trial.

Other Notes

Dr. Sidonio is a pediatric hematologist. At Children’s Healthcare of Atlanta (CHOA), he is a researcher, clinician, and the clinical director of the CHOA Hemophilia Treatment Center. In his director role at the center, he leads an initiative to standardize a strategy to diagnose and manage adolescent girls with heavy periods who often end up having VWD. He reports that he is using his own startup funds for this initiative. It is not clear yet if this is or will be a for-profit activity. He recently co-authored an article about the management of VWD, published in Hematology, The Education Program, <http://asheducationbook.hematologylibrary.org/content/2014/1/536.short?cited-by=yes&legid=bloodbook;2014/1/536&related-urls=yes&legid=bloodbook;2014/1/536>.